Abstract 603P
Background
Glioblastoma is a malignant brain tumour with a high recurrence rate following stanadard first-line treatment. While there are currently guidelines from NICE and EANO on the postoperative surveillance intervals for these patients, they were not evidence-based, and the quality of such recommendations remains untested. We therefore set out to provide an evidence-based recommendation on the optimal postoperative radiological surveillance schedule for glioblastoma patients after surgical treatment, tailored based on the extent of surgical resection and completion of adjuvant treatment.
Methods
This was a territory-wide, multicentre retrospective analysis of consecutive adult patients with IDH-wildtype glioblastoma treated with surgery and radiotherapy (RT) across seven neurosurgical units in Hong Kong between 2006-2020 (n=228). Data were extracted from the Hong Kong Glioblastoma Registry (HK-GBM Registry). Interval-censored Kaplan-Meier curves were constructed for the stratified groups based on the event-free survival of included patients, defined as time from the start date of RT to the occurrence of any event (tumour progression or death). A piecewise exponential model with different hazard functions in predefined time intervals was used to describe each curve. Accordingly, adopting a 15% event rate criterion, we generated the surveillance schedules.
Results
For a 15% event yield each scan (15% event rate criterion), we propose that glioblastoma patients treated with gross total resection be monitored with MRIs around every 9 weeks until 86 weeks after starting RT. Meanwhile, patients with residual tumour after surgery should be monitored more frequently at every 7 weeks until 75 weeks after RT initiation; and the interval should be further shortened to every 4 weeks for patients who were unable to complete the standard 6-weeks concurrent chemoradiotherapy.
Conclusions
Radiological surveillance is an important tool to detect postoperative tumour progression. The extent of surgical resection and completion of adjuvant treatment are major factors associated with glioblastoma progression and the frequency of radiological surveillance should therefore be guided by these two factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong Neuro-oncology Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract